Latest news with #IBAT
Cision Canada
3 days ago
- Business
- Cision Canada
INTERNATIONAL BATTERY METALS LTD. ANNOUNCES MICHAEL RUTLEDGE AS CHIEF FINANCIAL OFFICER OF THE COMPANY
VANCOUVER, BC and HOUSTON, June 2, 2025 /CNW/ - International Battery Metals Ltd. (" IBAT" or the " Company") (TSXV: IBAT) is pleased to announce the appointment of Michael Rutledge to serve as Chief Financial Officer of the Company. Prior to his appointment as Chief Financial Officer, Mr. Rutledge has served as interim Chief Financial Officer of the Company since March 6, 2025. Mr. Rutledge, CPA, is a seasoned financial executive with extensive experience as chief financial officer of multiple publicly traded companies across various industries. He has a strong background in corporate finance, SEC reporting, and strategic growth initiatives, including IPOs and M&A. Joseph Mills, Chief Executive Officer commented "We are very pleased to have Michael joining the leadership team at IBAT. During Michael's tenure as Interim CFO, he has proven strong leadership qualities and has worked tirelessly to help the IBAT team move the Company to its strategic goals of deploying the first large scale commercial DLE technology. We are very excited to welcome Michael to the leadership team ". In accordance with Mr. Rutledge's employment agreement with the Company (the " Employment Agreement") and the Company's restricted share unit plan (the " RSU Plan"), the Company has granted to Mr. Rutledge 450,000 restricted share units (" RSU"), which RSUs will vest in full on the first anniversary of their date of issuance and an additional 900,000 RSUs, which RSUs will vest in full on the date that the Company completes the building and deployment (with secured financing) of two additional Direct Lithium Extraction plants (in addition to the exiting DLE plant that the Company is currently planning to deploy). All RSUs are subject to accelerated vesting in the event of change in control and the terms and conditions of the RSU Plan. About International Battery Metals Ltd. The Company's direct lithium extraction technology is based on proprietary lithium extraction media housed in patented extraction towers that are enclosed in a modular, transportable platform that is able to be loaded and brought into production within a condensed time frame after arrival on a customer site. Utilizing the patented technology, the Company's focus has been on advanced extraction of lithium chloride from ground water salt brine deposits and returning the same water to the subsurface aquifer. The Company's unique patented technology ensures faster delivery of lithium chloride while ensuring minimal environmental impact. " Joseph A. Mills" Joseph A. Mills, CEO (832) 683-8839 Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This news release contains certain information that may constitute "forward-looking statements" under applicable Canadian securities legislation. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives or future events or performance (often, but not always, using words or phrases such as "seek", "anticipate", "plan", "continue", "estimate", "expect", "may", "will", "project", "predict", "forecast", "potential", "target", "intend", "could", "might", "should", "believe" and similar expressions) are not statements of historical fact and may be "forward- looking statements". Actual results may vary from forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause IBAT's actual results, performance, achievements, and future events to be materially different from the results, performance, achievement, or future events expressed or implied therein. Factors that could affect the outcome include, among others: future prices and the supply of lithium and other metals, the future demand for lithium and other metals, inability to raise the money necessary to incur the expenditures required to advance the Company's business strategies and objectives, general business, economic, competitive, political, and social uncertainties, results relating to its extraction technologies, failure to obtain regulatory or shareholder approvals (if required). IBAT believes that the expectations reflected in these forward-looking statements are reasonable, however there can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking statements. All forward-looking statements contained in this press release are given as of the date hereof and are based upon the opinions and estimates of management and information available to management as at the date hereof. IBAT disclaims any intention or obligation to update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
Yahoo
3 days ago
- Business
- Yahoo
INTERNATIONAL BATTERY METALS LTD. ANNOUNCES MICHAEL RUTLEDGE AS CHIEF FINANCIAL OFFICER OF THE COMPANY
VANCOUVER, BC and HOUSTON, June 2, 2025 /CNW/ - International Battery Metals Ltd. ("IBAT" or the "Company") (TSXV: IBAT) is pleased to announce the appointment of Michael Rutledge to serve as Chief Financial Officer of the Company. Prior to his appointment as Chief Financial Officer, Mr. Rutledge has served as interim Chief Financial Officer of the Company since March 6, 2025. Mr. Rutledge, CPA, is a seasoned financial executive with extensive experience as chief financial officer of multiple publicly traded companies across various industries. He has a strong background in corporate finance, SEC reporting, and strategic growth initiatives, including IPOs and M&A. Joseph Mills, Chief Executive Officer commented "We are very pleased to have Michael joining the leadership team at IBAT. During Michael's tenure as Interim CFO, he has proven strong leadership qualities and has worked tirelessly to help the IBAT team move the Company to its strategic goals of deploying the first large scale commercial DLE technology. We are very excited to welcome Michael to the leadership team ". In accordance with Mr. Rutledge's employment agreement with the Company (the "Employment Agreement") and the Company's restricted share unit plan (the "RSU Plan"), the Company has granted to Mr. Rutledge 450,000 restricted share units ("RSU"), which RSUs will vest in full on the first anniversary of their date of issuance and an additional 900,000 RSUs, which RSUs will vest in full on the date that the Company completes the building and deployment (with secured financing) of two additional Direct Lithium Extraction plants (in addition to the exiting DLE plant that the Company is currently planning to deploy). All RSUs are subject to accelerated vesting in the event of change in control and the terms and conditions of the RSU Plan. About International Battery Metals Ltd. The Company's direct lithium extraction technology is based on proprietary lithium extraction media housed in patented extraction towers that are enclosed in a modular, transportable platform that is able to be loaded and brought into production within a condensed time frame after arrival on a customer site. Utilizing the patented technology, the Company's focus has been on advanced extraction of lithium chloride from ground water salt brine deposits and returning the same water to the subsurface aquifer. The Company's unique patented technology ensures faster delivery of lithium chloride while ensuring minimal environmental impact. "Joseph A. Mills" Joseph A. Mills, CEO (832) 683-8839 Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This news release contains certain information that may constitute "forward-looking statements" under applicable Canadian securities legislation. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives or future events or performance (often, but not always, using words or phrases such as "seek", "anticipate", "plan", "continue", "estimate", "expect", "may", "will", "project", "predict", "forecast", "potential", "target", "intend", "could", "might", "should", "believe" and similar expressions) are not statements of historical fact and may be "forward- looking statements". Actual results may vary from forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause IBAT's actual results, performance, achievements, and future events to be materially different from the results, performance, achievement, or future events expressed or implied therein. Factors that could affect the outcome include, among others: future prices and the supply of lithium and other metals, the future demand for lithium and other metals, inability to raise the money necessary to incur the expenditures required to advance the Company's business strategies and objectives, general business, economic, competitive, political, and social uncertainties, results relating to its extraction technologies, failure to obtain regulatory or shareholder approvals (if required). IBAT believes that the expectations reflected in these forward-looking statements are reasonable, however there can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking statements. All forward-looking statements contained in this press release are given as of the date hereof and are based upon the opinions and estimates of management and information available to management as at the date hereof. IBAT disclaims any intention or obligation to update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as required by law. View original content to download multimedia: SOURCE International Battery Metals Ltd. View original content to download multimedia: Sign in to access your portfolio
Business Wire
19-05-2025
- Business
- Business Wire
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy served at Aimmune until its acquisition by Nestle Health Science in 2020. Before Aimmune, from 2007-2016, he was executive vice president, chief administrative officer, general counsel, and secretary of Codexis, Inc., a company focused on the development of synthetic enzymes for the pharmaceutical and food industries. Earlier in his career, he served in several roles within the legal department at CV Therapeutics. Mr. Sheehy began his career as a corporate and securities lawyer in Silicon Valley representing emerging growth companies and venture funds. Mr. Sheehy received an A.B. in History from Dartmouth College and a J.D. from American University's Washington College of Law. 'Doug brings extensive global legal experience that will strengthen Mirum's capabilities as we continue to grow our commercial business and advance our rare disease pipeline,' said Chris Peetz, chief executive officer at Mirum. 'Doug will be a great addition to Mirum's leadership team, and I look forward to leveraging his experience in guiding transformative growth for the company.' 'Mirum is an impressive company that has established its place as a leader in rare disease, and I am excited to have the opportunity to join the leadership team and contribute to the exciting work underway,' said Doug Sheehy. 'The company has a focused growth strategy and is poised for continued success as it works to make a meaningful difference in the lives of people impacted by rare disease.' About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution/LIVMARLI® (maralixibat) tablets, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum has initiated the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder. To learn more about Mirum, visit and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
Business Wire
23-04-2025
- Business
- Business Wire
Independent Bankers Association of Texas Partners with HC3 to Offer a Service That Enhances the Statement Experience for Customers
BIRMINGHAM, Ala.--(BUSINESS WIRE)--HC3, a statement partner for banks and credit unions, announced that it is a newly Endorsed Service Provider of The Independent Bankers Association of Texas (IBAT). Through the innovative methods of HC3, IBAT member banks have the opportunity to provide their account holders with secure, immediate access to statements from online and mobile banking channels. It is apparent that HC3 truly believes in the power of community banking. Its solutions are designed to assist community banks as they compete with national brands. HC3's solutions are proven to enhance operational efficiency and increase customer engagement and satisfaction. IBAT member banks that outsource their bank statements to HC3 can take advantage of document design solutions that showcase their brand identity while delivering an intuitive customer experience. Accompanying HC3's statement solutions are notices, end-of-year tax documents, document archival, Smart Campaign Manager for statement ads, and other ancillary solutions that help community bankers reduce distractions around their customer critical communications, including statement design offering, print and mail delivery, and digital delivery. HC3 partners with more than 700 financial institutions across the United States, with several processing facilities, including one in Dallas, Texas. 'It is apparent that HC3 truly believes in the power of community banking. Its solutions are designed to assist community banks as they compete with national brands,' says IBAT Services President Julie Courtney. 'By working with HC3, our bank members can experience an interface that makes it easy for them to track the various stages of production. They can rest assured that they will be well-supported in this area as they continue to focus their attention on those who live in the communities in which they serve.' 'HC3 is committed to providing products and services that help our community banking clients better serve their customers. As our market has evolved, we have adapted to stay at the forefront of our clients' needs,' says HC3 President Griffin McGahey. 'As part of that process, we are pleased to have the opportunity to partner with IBAT to offer its members key solutions that enhance a customer's statement experience.' About Independent Bankers Association of Texas Formed in 1974, the Independent Bankers Association of Texas (IBAT) represents Texas community banks. The Austin-based group is the largest state community banking organization in the nation, with membership comprised of more than 5,000 banks and branches in 700 Texas communities. Providing safe and responsible financial services to all Texans, IBAT member bank assets range in size from $28 million to $51 billion with combined assets statewide of nearly $296 billion. IBAT member banks are committed to supporting and investing in their local communities. For more information, visit About HC3 Headquartered in Birmingham, Ala., HC3 helps Financial Institutions create efficiencies that align with their unique needs - reducing costs and saving time with a smarter approach to statement processing. With HC3, FIs gain efficiency, and a strategic partner committed to their success. For more information, call (877) 838-2345 or visit
